nach oben

Tumor Biology

Erschienen in:

01.09.2014 | Research Article

H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT

verfasst von: Chenchao Ma, Kate Nong, Hongda Zhu, Weiwei Wang, Xinyu Huang, Zhou Yuan, Kaixing Ai

Erschienen in: Tumor Biology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

The long noncoding RNA (lncRNA) H19 has been recently characterized as an oncogenic lncRNA in some tumors. However, the role of H19 in pancreatic ductal adenocarcinoma (PDAC) remains unclear. In this study, we found that not only the levels of H19 was overexpressed in PDAC compared with adjacent normal tissues, but also H19 expression was upregulated remarkably in primary tumors which subsequently metastasized, compared to those did not metastasis. Subsequently, the efficacy of knockdown of H19 by H19-small interfering RNA (siRNA) was evaluated in vitro, and we found that downregulation of H19 impaired PDAC cell invasion and migration. We further demonstrated that H19 promoted PDAC cell invasion and migration at least partially by increasing HMGA2-mediated epithelial-mesenchymal transition (EMT) through antagonizing let-7. This study suggests an important role of H19 in regulating metastasis of PDAC and provides some clues for elucidating the lncRNA-miRNA functional network in cancer.

Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.CrossRefPubMed

Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.CrossRefPubMed

Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer. 2003;2:14.PubMedCentralCrossRefPubMed

Mattick JS. Makunin IV: Non-coding RNA. Hum Mol Genet. 2006;15 Spec No 1:R17-R29.

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.CrossRefPubMed

Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011;10:38.PubMedCentralCrossRefPubMed

Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41.CrossRefPubMed

Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. Febs Lett. 2010;584:4575–80.CrossRefPubMed

Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–14.PubMedCentralCrossRefPubMed

10.

Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1:391–407.PubMedCentralCrossRefPubMed

11.

Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA. 2007;13:313–6.PubMedCentralCrossRefPubMed

12.

Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays. 2010;32:473–80.CrossRefPubMed

13.

Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, Yang AS. Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res. 2007;67:10753–8.CrossRefPubMed

14.

Lottin S, Adriaenssens E, Dupressoir T, Berteaux N, Montpellier C, Coll J, et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis. 2002;23:1885–95.CrossRefPubMed

15.

Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One. 2007;2:e845.PubMedCentralCrossRefPubMed

16.

Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52:101–12.CrossRefPubMed

17.

Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60.PubMedCentralCrossRefPubMed

18.

Bussing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med. 2008;14:400–9.CrossRefPubMed

19.

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147:358–69.PubMedCentralCrossRefPubMed

20.

Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505:344–52.PubMedCentralCrossRefPubMed

21.

Yamaguchi H, Kojima T, Ito T, Kimura Y, Imamura M, Son S, et al. Transcriptional control of tight junction proteins via a protein kinase c signal pathway in human telomerase reverse transcriptase-transfected human pancreatic duct epithelial cells. Am J Pathol. 2010;177:698–712.PubMedCentralCrossRefPubMed

22.

Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21:1025–30.PubMedCentralCrossRefPubMed

23.

Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009;22:43–9.PubMedCentralCrossRefPubMed

24.

Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem. 2008;283:33437–46.PubMedCentralCrossRefPubMed

25.

Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 2007;13:4769–76.CrossRefPubMed

26.

Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. FEBS J. 2013;280:1709–16.CrossRefPubMed

27.

Ariel I, Miao HQ, Ji XR, Schneider T, Roll D, de Groot N, et al. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol. 1998;51:21–5.PubMedCentralCrossRefPubMed

28.

Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, et al. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res. 2006;4:283–92.CrossRefPubMed

29.

Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T, et al. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene. 1995;10:1193–8.PubMed

30.

Okamoto K, Morison IM, Taniguchi T, Reeve AE. Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci U S A. 1997;94:5367–71.PubMedCentralCrossRefPubMed

31.

Moulton T, Crenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, et al. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet. 1994;7:440–7.CrossRefPubMed

32.

Casola S, Pedone PV, Cavazzana AO, Basso G, Luksch R, D'Amore ES, et al. Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene. 1997;14:1503–10.CrossRefPubMed

33.

Saito Y, Suzuki H, Matsuura M, Sato A, Kasai Y, Yamada K, et al. Micrornas in hepatobiliary and pancreatic cancers. Front Genet. 2011;2:66.PubMedCentralCrossRefPubMed

34.

Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005;33:5394–403.PubMedCentralCrossRefPubMed

35.

Luo G, Long J, Cui X, Xiao Z, Liu Z, Shi S, et al. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Int J Oncol. 2013;42:979–84.PubMed

36.

Wang YY, Ren T, Cai YY, He XY. MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm. 2013;28:131–7.CrossRefPubMed

37.

Luo Y, Li W, Liao H. HMGA2 induces epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells. Oncol Lett. 2013;5:1353–6.PubMedCentralPubMed

38.

Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol. 2009;174:854–68.PubMedCentralCrossRefPubMed

39.

Liu Q, Liu T, Zheng S, Gao X, Lu M, Sheyhidin I, Lu X. HMGA2 is down-regulated by microRNA let-7 and associated with epithelial-mesenchymal transition in Kazakh's esophageal squamous cell carcinoma. Histopathology. 2014.

40.

Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, et al. HMGA2 is a driver of tumor metastasis. Cancer Res. 2013;73:4289–99.PubMedCentralCrossRefPubMed

41.

Zha L, Zhang J, Tang W, Zhang N, He M, Guo Y, et al. HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig Dis Sci. 2013;58:724–33.CrossRefPubMed

42.

Tan EJ, Thuault S, Caja L, Carletti T, Heldin CH, Moustakas A. Regulation of transcription factor twist expression by the DNA architectural protein high mobility group a2 during epithelial-to-mesenchymal transition. J Biol Chem. 2012;287:7134–45.PubMedCentralCrossRefPubMed

43.

Belge G, Radtke A, Meyer A, Stegen I, Richardt D, Nimzyk R, et al. Upregulation of the high mobility group AT-hook 2 gene in acute aortic dissection is potentially associated with endothelial-mesenchymal transition. Histol Histopathol. 2011;26:1029–37.PubMed

44.

Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. Transforming growth factor-β employs HMGA2 to elicit epithelial–mesenchymal transition. J Cell Biol. 2006;174:175–83.PubMedCentralCrossRefPubMed

Titel: H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT
verfasst von: Chenchao Ma
Kate Nong
Hongda Zhu
Weiwei Wang
Xinyu Huang
Zhou Yuan
Kaixing Ai
Publikationsdatum: 01.09.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 9/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2185-5

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT

Abstract

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis

Podoplanin—a novel marker in oral carcinogenesis

RETRACTED ARTICLE: Single-nucleotide polymorphisms of LIG1 associated with risk of lung cancer

Establishment of experimental implantation tumor models of hepatocellular carcinoma in Wistar rats

Regulation of metastasis of pediatric multiple myeloma by MMP13

TPM3, a strong prognosis predictor, is involved in malignant progression through MMP family members and EMT-like activators in gliomas

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie